# Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients.

> **NCT03902769** · NA · UNKNOWN · sponsor: **Rambam Health Care Campus** · enrollment: 160 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Prescribing conventional chemotherapy while with holding allo-SCT

## Key facts

- **NCT ID:** NCT03902769
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-15
- **Primary completion:** 2021-11-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2019-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03902769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03902769, "Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03902769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*